Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Marts 2013

Planlagt Fastgjort Låst Flyttet Genmab
190 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • D Offline
    D Offline
    deleted-user
    wrote on sidst redigeret af
    #42

    Hvem er ham Tardif?

    1 Reply Last reply
    0
    • MadsSkjernM Offline
      MadsSkjernM Offline
      MadsSkjern
      wrote on sidst redigeret af
      #43

      Hotshot kardiolog i Canada http://www.genomequebec.com/1149-investigator/jean-claude-tardif.html

      1 Reply Last reply
      0
      • D Offline
        D Offline
        deleted-user
        wrote on sidst redigeret af
        #44

        jeg kan ikke rigtigt åbne det link

        1 Reply Last reply
        0
        • MadsSkjernM Offline
          MadsSkjernM Offline
          MadsSkjern
          wrote on sidst redigeret af
          #45

          Jean-Claude Tardif is presently the director of the research center at the Montreal Heart Institute, professor of medicine at the University of Montreal, and founder of the new University of Montreal Pharmacogenomics Centre. Dr. Tardif is a world leader in cardiovascular research and has made groundbreaking contributions to the fields of atherosclerosis and biomarkers to assess anti-atherosclerotic therapies. He has published 180 scientific articles in prestigious journals, written 25 book chapt

          1 Reply Last reply
          0
          • D Offline
            D Offline
            deleted-user
            wrote on sidst redigeret af
            #46

            ok.

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #47

              Duo Body http://www.pnas.org/content/early/2013/03/08/1220145110.full.pdf+html

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #48

                This superior activity does, however, suggest that some antibody
                pairs may benefit more from a bsAb approach than from a combination
                strategy.

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #49

                  using cFAE to create bsIgG1 ensures a proper in
                  vivo half-life, intact Fc effector functions, and good manufacturability
                  while retaining a regular IgG structure.

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #50

                    Proof-of-concept studies with HER2×CD3 (T-cell recruitment)
                    and HER2×HER2 (dual epitope targeting) bsAbs demonstrate
                    superior in vivo activity compared with parental antibody pairs.

                    1 Reply Last reply
                    0
                    • D Offline
                      D Offline
                      deleted-user
                      wrote on sidst redigeret af
                      #51

                      Just a moment...

                      favicon

                      (www.pnas.org)

                      1 Reply Last reply
                      0
                      • D Offline
                        D Offline
                        deleted-user
                        wrote on sidst redigeret af
                        #52

                        det her link er måske bedre

                        1 Reply Last reply
                        0
                        • 1 Offline
                          1 Offline
                          120281
                          wrote on sidst redigeret af
                          #53

                          går gang i Gen igen idag. 5% oppe.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #54

                            Clinical trials tæller 93 ofatumumab idag efter langtid at have haft 92. Jeg kan bare ikke finde det nye ...

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #55

                              Tror det er denne http://www.clinicaltrials.gov/ct2/show/NCT01809847?term=ofatumumab&lup_s=03%2F08%2F2013&lup_e=03%2F13%2F2013&rank=2

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #56

                                Det bliver interessant om Winkel vil sælge nogle af de tegnede aktier - eller om han går planken ud 🙂

                                1 Reply Last reply
                                0
                                • investor1989I Offline
                                  investor1989I Offline
                                  investor1989
                                  wrote on sidst redigeret af
                                  #57

                                  Har det her været fremme?? http://finance.yahoo.com/news/aeterna-zentaris-discontinue-phase-3-151500409.html en af Daratumumabs konkurrenter allerede i phase III har stoppet udviklingen.

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #58

                                    Det gør jo ikke daratumumab mindre interessant og kan måske forklare
                                    , at der ikke sker noget mht kombistudiet med Velcade. som vi er flere der har savnet

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #59

                                      Det kunne være man skulle læse teksten - ikke Velcade der har problemet !

                                      1 Reply Last reply
                                      0
                                      • FantomasF Offline
                                        FantomasF Offline
                                        Fantomas
                                        wrote on sidst redigeret af
                                        #60

                                        Ville man ikke normalt vente med at udnytte sine warrents til sidste dag før udløb (af hensyn til risikominimering), hvis man ønskede at beholde aktierne? Er der nogen der ved om winkels warrents var ved at udløbe?

                                        1 Reply Last reply
                                        0
                                        • FantomasF Offline
                                          FantomasF Offline
                                          Fantomas
                                          wrote on sidst redigeret af
                                          #61

                                          De nye aktier er i øvrigt tegnet til kurs 72,6 (i gennemsnit)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger